Biogen

Data at EULAR back Biogen, UCB's first-in-class lupus drug pharmaphorum08:40Pharma Biotech

Biogen taps City Therapeutics in RNAi deal worth up to $1B ENDPOINTS14:26Pharma Biotechnology Biotech

Biogen, UCB take a leap in lupus with promising phase 3 results Benzinga16:59Pharma Biotech

Breakthrough gene-targeted drug for Als patients launched in China CGTN03:43Pharma Biotech China

Minita shah-Mara named CPO at blue cross of Massachusetts HRO Today14:08Massachusetts Business Massachusetts Pharma

Is biogen stock underperforming the s&p 500? Barchart11:16Stock Markets (World) Stock Market (US) S&P 500

Biogen and City Therapeutics to develop RNAi therapy Pharmaceutical Technology10:10Pharma Biotech

Biogen and City Therapeutics to develop RNAi therapies in deal worth over $1bn PMLiVE12:37Pharma Biotech

Biogen (nasdaqgs:BIIB) partners with City Therapeutics in US$1 billion RNAi therapy deal Simply Wall St21:53Pharma Biotech

Latest News

In the last 7 days

Data at EULAR back Biogen, UCB's first-in-class lupus drug pharmaphorum08:40 13-Jun-25

Biogen, UCB Take A Leap In Lupus With Promising Phase 3 Results Benzinga16:59 12-Jun-25

Minita Shah-Mara Named CPO at Blue Cross of Massachusetts HRO Today14:08 12-Jun-25

Is Biogen Stock Underperforming the S&P 500? Barchart11:16 12-Jun-25

Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show… Biogen (Press Release)06:02 12-Jun-25

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases Scrip Pharma Intelligence22:19 11-Jun-25

Biogen Highlights the Potential of Felzartamab for a Range of Immune-Mediated Diseases Including Three Phase 3 Programs … Biogen (Press Release)13:41 11-Jun-25

Breakthrough gene-targeted drug for Als patients launched in China CGTN03:43 11-Jun-25

Ill. Judge Questions Standing In Biogen Antitrust Suit Law36001:54 11-Jun-25

Judge To Limit Experts in Biogen, Genentech Drug Royalty Trial Law36003:49 10-Jun-25

In the last month

Biogen Announces Webcast of Annual Meeting of Stockholders Biogen (Press Release)21:16 5-Jun-25

Deal Watch: Lilly Licenses Camurus’s Delivery Technology For Long-Acting Incretins Scrip Pharma Intelligence22:36 4-Jun-25

Biogen to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference Biogen (Press Release)22:35 3-Jun-25

Biogen and City Therapeutics to develop RNAi therapies in deal worth over $1bn PMLiVE12:37 29-May-25

Biogen taps start-up for RNAi collaboration Chemical & Engineering News16:55 28-May-25

Biogen and City Therapeutics to develop RNAi therapy Pharmaceutical Technology10:10 28-May-25

City hits the town with $1B-plus deal with Biogen BioWorld21:59 27-May-25

Biogen (NasdaqGS:BIIB) Partners With City Therapeutics in US$1 Billion RNAi Therapy Deal Simply Wall St21:53 27-May-25

Biogen taps City Therapeutics in RNAi deal worth up to $1B ENDPOINTS14:26 27-May-25

Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies Biogen (Press Release)12:33 27-May-25

September 2026 Options Now Available For Biogen (BIIB) Nasdaq16:34 23-May-25

Biogen Files Suit Against Neurimmune Over Rights to Bispecific Antibody JD Supra20:02 22-May-25

Do Wall Street Analysts Like Biogen Stock? Barchart12:59 20-May-25

For Eisai and Biogen's Leqembi, first FDA-approved Alzheimer's blood test will take time to… FiercePharma19:07 19-May-25

Five years, one approval: Europe’s slow march on Alzheimer’s treatments Pharmaceutical Technology16:25 19-May-25

view more headlines

13 Jun 08:40

About our Biogen News

Biogen is an American multinational biotechnology company that specialises in treatment of neurological diseases.

Publication filters

Sorry, no headlines or news topics were found. Please try different keywords.